DVAX Dynavax: יחס שווי חברה להכנסות

The EV/Sales business valuation reflects the asset's dynamics, with the current level sitting around 4421.68. The team of immunologist experts at Dynavax Technologies (DVAX) is developing innovative vaccines supported by stable funding. The biopharmaceutical company is capturing the global immunization market by offering pharmacies the effective drug Heplisav-B. A sustainable market moat is provided by a unique adjuvant that accelerates immunity formation and guarantees a high commercial share.
פילוחי מדדים פיננסיים ומדדי שוק עבור Dynavax Pharma (DVAX)

This metric combines market capitalization and net debt, comparing the total enterprise value to annual sales volume. The stability of this value confirms the fundamental resilience of the enterprise regardless of its debt load. By analyzing the EV-to-revenue ratio, an investor determines the fair valuation of assets. For Dynavax Technologies (DVAX), this reflects the balance between core vaccination income and R&D expenditures. The current market share of the product provides a solid foundation for valuation.